Get to know Cytomx better with 6 real example sentences.
Cytomx in a sentence
Using Cytomx
- In the example corpus, cytomx often appears in combinations such as: cytomx therapeutics, that cytomx.
Context around Cytomx
- Average sentence length in these examples: 21 words
- Position in the sentence: 2 start, 3 middle, 1 end
- Sentence types: 6 statements, 0 questions, 0 exclamations
Corpus analysis for Cytomx
- In this selection, "cytomx" usually appears in the middle of the sentence. The average example has 21 words, and this corpus slice is mostly made up of statements.
- Around the word, assess, follow and therapeutics stand out and add context to how "cytomx" is used.
- Recognizable usage signals include cytomx therapeutics has and evidence that cytomx therapeutics is. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "cytomx" sits close to words such as aaas, aacc and aacs, which helps place it inside the broader word index.
Example types with cytomx
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
However, there’s evidence that CytomX Therapeutics is in excellent fiscal condition. (12 words)
CytomX Therapeutics has a twelve month low of $3.60 and a twelve month high of $12.63. (18 words)
On average, equities analysts expect that CytomX Therapeutics will post -2.02 EPS for the current fiscal year. (18 words)
BMO Capital Markets raised their price target on CytomX Therapeutics from $3.25 to $3.59 and gave the stock a “market perform” rating in a research report on Thursday, May 9th. (32 words)
Together, they’ll assess CytomX Therapeutics’ cytokine, CX-801, in a combination therapy with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), to treat tumors. (25 words)
Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow CytomX Therapeutics. (21 words)
Example sentences (6)
BMO Capital Markets raised their price target on CytomX Therapeutics from $3.25 to $3.59 and gave the stock a “market perform” rating in a research report on Thursday, May 9th.
However, there’s evidence that CytomX Therapeutics is in excellent fiscal condition.
Together, they’ll assess CytomX Therapeutics’ cytokine, CX-801, in a combination therapy with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), to treat tumors.
CytomX Therapeutics has a twelve month low of $3.60 and a twelve month high of $12.63.
On average, equities analysts expect that CytomX Therapeutics will post -2.02 EPS for the current fiscal year.
Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow CytomX Therapeutics.
Common combinations with cytomx
These word pairs occur most frequently in English texts: